The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11033 malaria professionals are enjoying the free benefits of MalariaWorld today

Plasmodium vivax

Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study

June 5, 2021 - 07:23 -- Open Access
Devine A, Battle KE, Meagher N, Howes RE, Dini S, Gething PW, Simpson JA, Price RN, Lubell Y
PLoS Med. 2021 Jun 1;18(6):e1003614

In 2017, an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of vivax malaria is largely driven by its ability to form dormant liver stages (hypnozoites) that can reactivate to cause recurrent episodes of malaria. Elimination of both the blood and liver stages of the parasites (“radical cure”) is required to achieve a sustained clinical response and prevent ongoing transmission of the parasite. Novel treatment options and point-of-care diagnostics are now available to ensure that radical cure can be administered safely and effectively. We quantified the global economic cost of vivax malaria and estimated the potential cost benefit of a policy of radical cure after testing patients for glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study

June 1, 2021 - 15:51 -- Open Access
Kho S, Qotrunnada L, Anstey NM, et al.
PLoS Med. 2021 May 26;18(5):e1003632

A very large biomass of intact asexual-stage malaria parasites accumulates in the spleen of asymptomatic human individuals infected with Plasmodium vivax. The mechanisms underlying this intense tropism are not clear. We hypothesised that immature reticulocytes, in which P. vivax develops, may display high densities in the spleen, thereby providing a niche for parasite survival.

Not Open Access | Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria

June 1, 2021 - 15:45 -- NOT Open Access
Suarez-Kurtz G
Clin Pharmacol Ther. 2021 May 27

Plasmodium vivax is the most widespread human malaria parasite, with 2.5 billion people at risk of infection worlwide. P. vivax forms liver hypnozoites which trigger further symptomatic episodes (relapses) weeks or months after the initial episode. Radical cure of vivax malaria requires hypnozoitocide therapy to prevent relapses. The two FDA-approved hypnozoiticides for human use, primaquine and tafenoquine, are pro-drugs, that require in vivo conversion into metabolites with redox activity. This mini-review focuses on the association between CYP2D6-mediated hydroxylation and hypnozoiticide efficacy of primaquine and tafenoquine.

Distinctive genetic structure and selection patterns in Plasmodium vivax from South Asia and East Africa

June 1, 2021 - 15:36 -- Open Access
Benavente ED, Manko E, Clark TG, et al.
Nat Commun. 2021 May 26;12(1):3160

Despite the high burden of Plasmodium vivax malaria in South Asian countries, the genetic diversity of circulating parasite populations is not well described. Determinants of antimalarial drug susceptibility for P. vivax in the region have not been characterised. Our genomic analysis of global P. vivax (n = 558) establishes South Asian isolates (n = 92) as a distinct subpopulation, which shares ancestry with some East African and South East Asian parasites.

NOT Open Access | Plasmodium vivax and Neisseria meningitidis co-infection in a newborn

June 1, 2021 - 15:24 -- NOT Open Access
Ordoñez Díaz KM, Gutiérrez Paternina JJ
Trop Doct. 2021 May 27:494755211017419

Invasive infections due to Neisseria meningitidis in Colombia are unusual in newborns, in contrast to infections due to Plasmodium vivax which is one of the main pathogens related to the presentation of fever in this age group, especially in the indigenous population.

NOT Open Access | Transmission of malaria from donors to solid organ transplant recipients: A case report and literature review

June 1, 2021 - 12:59 -- NOT Open Access
Rosso F, Agudelo Rojas OL, Suarez Gil CC, Lopez Vargas JA, Gómez-Mesa JE, Carrillo DC, Meza Ramirez L, Caicedo Rusca LA
Transpl Infect Dis. 2021 May 31:e13660

Malaria is a febrile and potentially fatal infection. It is typically transmitted to humans through the bite of Anopheles mosquitoes and less frequently can be contracted through blood transfusions, sharing contaminated needles and syringes, mother-to-child transmission, or after solid organ transplantation (SOT). Posttransplant malaria has rarely been reported in the literature, even in endemic areas. We report the cases of three solid organ recipients in which Plasmodium vivax infection was documented during postsurgical evaluation 30 days after transplant surgery.

NOT Open Access | High proportion of genome-wide homology and increased pre-treatment pvcrt levels in Plasmodium vivax late recurrences: a chloroquine therapeutic efficacy study

May 26, 2021 - 09:40 -- NOT Open Access
Rovira-Vallbona E, Van Hong N, Rosanas-Urgell A, et al.
Antimicrob Agents Chemother. 2021 May 24:AAC.00095-21

Chloroquine (CQ) is the first-line treatment for Plasmodium vivax malaria in most endemic countries. Monitoring P.vivax CQ resistance (CQR) is critical but remains challenged by the difficulty to distinguish real treatment failure from reinfection or liver relapse. Therapeutic efficacy of CQ against uncomplicated P.vivax malaria was evaluated in Gia Lai province, Vietnam. Sixty-seven patients were enrolled and followed-up for 42 days using microscopy and (RT)qPCR.

NOT Open Access | Plasmodium vivax vaccine candidate MSP1 displays conserved B-cell epitope despite high genetic diversity

May 25, 2021 - 14:54 -- NOT Open Access
Ghoshal S, Kanjilal SD, Sengupta S
Infect Genet Evol. 2021 May 19:104929

The polymorphic nature of merozoite surface protein 1(MSP1) raises doubts whether it may serve as a vaccine target against Plasmodium vivax malaria. This study analyses the impact of genetic variability on the epitope organization of different Pvmsp1 blocks. Ten blood samples collected from P. vivax infected malaria patients from West Bengal, India were used to analyze sequence and antigenic diversities of block 2 region of Pvmsp1.

Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study)

May 19, 2021 - 14:00 -- Open Access
Brito-Sousa JD, Murta F, Lacerda MVG, et al.
PLoS Negl Trop Dis. 2021 May 18;15(5):e0009415

Glucose-6-phosphate dehydrogenase (G6PD) deficiency greatly hinders Plasmodium vivax malaria radical cure and further elimination due to 8-aminoquinolines-associated hemolysis. Although the deleterious health effects of primaquine in G6PD deficient individuals have been known for over 50 years, G6PD testing is not routinely performed before primaquine treatment in most P. vivax endemic areas.

Contrasting Epidemiology and Genetic Variation of Plasmodium vivax Infecting Duffy Negatives across Africa

May 19, 2021 - 13:24 -- Open Access
Lo E, Russo G, Paganotti GM, et al.
Int J Infect Dis. 2021 May 12:S1201-9712(21)00410-0

Plasmodium vivax malaria was thought to be rare in Africans who lack the Duffy blood group antigen expression. However, recent studies indicate that P. vivax can infect Duffy-negative individuals and has penetrated into areas of high Duffy-negativity across Africa. This study compares epidemiological and genetic features of P. vivax between African regions.


Subscribe to RSS - Plasmodium vivax